[1] 魏安华,李娟.《中国心力衰竭诊断和治疗指南2018》药物更新透视[J].医药导报,2019,38(5):539-543.
[2] 段娟. 观察沙库巴曲缬沙坦治疗高龄射血分数降低型心力衰竭患者的临床疗效[J].心血管病防治知识:学术版,2020,10(25):27-29.
[3] Greene SJ, Fonarow GC, Vaduganathan M, et al.The vulnerable phase after hospitalization for heart failure[J]. Nat Rev Cardiol,2015,12(4):220-229.
[4] 牛潇玉. 沙库巴曲缬沙坦治疗难治性心力衰竭的效果及预后研究[D].郑州大学,2019.
[5] 李薇, 高景芳, 贾凡,等.沙库巴曲缬沙坦对射血分数降低性心力衰竭患者心力衰竭易损期的疗效[J].中国临床药理学杂志,37(14):1842-1845.
[6] 徐立庆,付强,李铎,等.沙库巴曲缬沙坦钠片治疗射血分数降低慢性心力衰竭患者的疗效分析[J].中国实用医药,2021, 16(24):105-108.
[7] Yandrapalli S, Aronow WS, Mondal P, et al.The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan[J]. Arch Med Sci, 2017, 13(5):1207-1216.
[8] 郑捷,刘亚娟,杨继敏.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的疗效及对患者血清学指标的影响[J].当代医学,2021,27(33):4-6.
[9] 张相杰,黄文平,许有凡.沙库巴曲缬沙坦和盐酸贝那普利片对心力衰竭患者心室重塑、炎症因子的影响[J].实用医学杂志,2019,35(5):125-129.
[10] Velazquez EJ, Morrow DA, DeVore AD, et al. Rationale and design of the comparison of sacubitril/valsartan versus enalapril on effect on NT-pro-BNP in patients stabilized from an acute heart failure episode (PIONEER-HF) trial[J]. Am Heart J, 2018 (198):145-151.
[11] 黄静萍,马娟,陈吉丽,等.沙库巴曲缬沙坦治疗射血分数降低心力衰竭患者的临床疗效分析[J].心血管病防治知识(下半月),2019,9(36):38-40. |
